MEDICINA
Departamento
Leiden University Medical Center
Leiden, HolandaPublicaciones en colaboración con investigadores/as de Leiden University Medical Center (34)
2023
-
Characteristics of individuals with alpha-1 antitrypsin deficiency from Northern and Southern European countries: EARCO international registry
The European respiratory journal
-
Correction: Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry (Respiratory Research, (2022), 23, 1, (352), 10.1186/s12931-022-02275-4)
Respiratory Research
2022
-
Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry
Respiratory Research, Vol. 23, Núm. 1
-
Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis
npj Genomic Medicine, Vol. 7, Núm. 1
2021
-
Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
Annals of the Rheumatic Diseases, Vol. 80, Núm. 8, pp. 1040-1047
-
Genomic Risk Score impact on susceptibility to systemic sclerosis
Annals of the Rheumatic Diseases, Vol. 80, Núm. 1, pp. 118-127
-
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433
-
Thyroid function is not associated with brown adipose tissue volume and 18F-fluorodeoxyglucose uptake in young euthyroid adults
European Journal of Endocrinology, Vol. 185, Núm. 2, pp. 209-218
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLoS ONE, Vol. 14, Núm. 2
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
-
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911
-
The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab: results from the FREEDOM and FREEDOM Extension studies
Osteoporosis International, Vol. 30, Núm. 1, pp. 71-78
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
-
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLoS ONE, Vol. 13, Núm. 5
2017
-
An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis
Journal of Rheumatology, Vol. 44, Núm. 10, pp. 1453-1457
-
Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort
Arthritis and Rheumatology, Vol. 69, Núm. 6, pp. 1337-1338
-
Cardiovascular efficacy and safety of bococizumab in high-risk patients
New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539
-
Increased expression of microRNA-155 in peripheral blood mononuclear cells from psoriasis patients is related to disease activity
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 2, pp. 312-322